HIV Medicine最新文献

{"title":"Willingness to participate in clinical trials and expectations towards antiretroviral therapy among heavily treatment-experienced people living with HIV: A feasibility survey.","authors":"Marie Ballif, Manuela Correia da Silva Saúde, David Haerry, Marcel Stoeckle, Patrick Schmid, Dominique Braun, Alexandra Calmy, Gilles Wandeler, Bernard Surial","doi":"10.1111/hiv.70053","DOIUrl":"https://doi.org/10.1111/hiv.70053","url":null,"abstract":"<p><strong>Introduction: </strong>As life expectancy among persons with HIV on antiretroviral therapy (ART) is increasing, comorbidities and polypharmacy increase. Drug-drug interactions (DDIs) are common among persons with HIV with a history of virological failure, since many are receiving boosted ART. We assessed the willingness of individuals with a history of virological failure on a boosted ART to participate in simplification trials and evaluated their expectations towards ART.</p><p><strong>Methods: </strong>We conducted a cross-sectional survey among persons with HIV at five hospitals in Switzerland between October 2021 and July 2022. We collected data using quantitative paper-based questionnaires and analysed the data using descriptive statistics. Community representatives were involved in the study planning and conduct, and in the interpretation of findings.</p><p><strong>Results: </strong>Overall, 143 (64%) of 223 eligible persons with HIV participated. Median age was 59 years (interquartile range [IQR] 52.5-63.5), 32 (22%) were female, median time on ART was 26 years (IQR: 20-27). Among participants, 104 (72%) would agree to participate in clinical trials aiming at evaluating simplified ART regimens with reduced DDI risks, or were still undecided. Of them, 92 (88%) were satisfied with their current treatment. Their main expectations about simplified ART were treatment efficacy (91%), fewer DDIs (83%), low pill number (78%) and forgiveness in case of missed doses (75%).</p><p><strong>Conclusions: </strong>Persons with HIV and a history of virological failure were motivated to participate in clinical research. This underlines the importance of including them in future trials. Furthermore, conducting feasibility surveys and including persons with HIV in the study design prior to trials ensures their relevance and alignment with people's needs and expectations.</p>","PeriodicalId":13176,"journal":{"name":"HIV Medicine","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-06-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144247672","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Causes of death in people living with HIV from a North London cohort between 2006 and 2023: A descriptive analysis.","authors":"Linda Cheyenne Vaccari, Damien K Ming, Jane Hazell, Alan Hunter, Fiona M Burns, Robert F Miller","doi":"10.1111/hiv.70054","DOIUrl":"https://doi.org/10.1111/hiv.70054","url":null,"abstract":"<p><strong>Background: </strong>The provision of highly active anti-retroviral therapy has improved outcomes for people with HIV, worldwide. There are few data on trends and changes in the cause of death among people with HIV in the United Kingdom since its advent.</p><p><strong>Methods: </strong>We retrospectively reviewed deaths in people attending HIV services at Royal Free Hospital London between 2006 and 2023. Cause of death was categorized using the CoDe protocol. Analysis included description of demographics over time, HIV-specific metrics (late diagnoses, AIDS-defining illnesses) and aspects related to HIV treatment and trends in non-AIDS-related causes of death.</p><p><strong>Results: </strong>Of 529 deaths, 79.8% were male. Cause of death was non-AIDS-defining malignancy 21.4%, non-AIDS-defining infection 12.1%, AIDS-defining infection 11.2%, AIDS-defining malignancy 7.8%, self-harm 9.3%, cardiovascular 8.3%, liver 2.8%, respiratory 2.6%, other 7.2% and unknown 17.4%. Comparing 2006-2011 and 2018-2023, the proportion of those dying from AIDS-defining infection and malignancy fell from 13.8% to 7.1%, and from 13.8% to 3.1%, respectively; median age at death increased from 44.9 years (interquartile range [IQR] 39.7-52.4) to 58.0 (IQR 52.0-67.7): p < 0.001 and median interval between HIV diagnosis and death increased from 8.5 years (IQR 2.9-14.0) to 19.1 (IQR 11.8-26.1): p < 0.001.</p><p><strong>Conclusions: </strong>Between 2006 and 2023, there was a significant increase in median age at death and in the interval between HIV diagnosis and death. The proportion of deaths associated with AIDS-defining infection and malignancy fell, while non-AIDS-defining infection, malignancy and deaths from self-harm increased. These data suggest that focusing on earlier diagnosis, holistic clinical management and support for mitigating modifiable lifestyle risk factors including cancer screening and mental health services could result in improved outcomes and reduce preventable deaths.</p>","PeriodicalId":13176,"journal":{"name":"HIV Medicine","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144225337","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Driving progress towards PrEP equity: Key changes in the 2025 BASHH/BHIVA UK PrEP guidelines","authors":"Dan Clutterbuck,&nbsp;Michael Brady,&nbsp;Alison Rodger","doi":"10.1111/hiv.70043","DOIUrl":"https://doi.org/10.1111/hiv.70043","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>Success in HIV prevention interventions, including pre-exposure prophylaxis (PrEP), among gay, bisexual and other men-who-have-sex-with-men (GBMSM) has not been replicated across all communities. The 2025 BASHH/BHIVA UK PrEP Guidelines recognizes and addresses the significant barriers and constraints that existing guidance and service delivery models place on PrEP access and equity. This paper summarizes the key guideline recommendations and the rationale supporting them.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>The guidelines were developed following the methodology described in the CEG Framework for Guideline development published on the BASHH website. The writing group of clinicians, academics and community advocates incorporated input from a formal public consultation process.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The 2025 guideline includes over 90 graded recommendations. A chapter on PrEP equity and an updated chapter on PrEP suitability and risk assessment, moving away from basing PrEP eligibility on the inclusion criteria used for clinical trials, are included. Injectable PrEP has demonstrated superiority to oral PrEP but presents challenges in delivery, so improving equity in access and uptake of existing oral PrEP options was a key priority. The guidelines simplify and clarify advice on dosing for oral PrEP and recommend new event-based dosing options for all PrEP users, including quick-start double-dose PrEP for everybody. New guidance on the use of PrEP after a potential exposure is also included.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The PrEP guidelines purposefully highlight equity, access and the urgent requirement to meet the needs of underserved communities as a priority. These are addressed through pragmatic and groundbreaking recommendations based on careful consideration of all available evidence.</p>\u0000 </section>\u0000 </div>","PeriodicalId":13176,"journal":{"name":"HIV Medicine","volume":"26 7","pages":"1125-1141"},"PeriodicalIF":2.8,"publicationDate":"2025-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/hiv.70043","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144520086","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Enhancing sexually transmitted and blood-borne infection prevention in opioid-agonist therapy programmes: Lessons from a canadian pragmatic trial and implications for Taiwan.","authors":"Shu-Chuan Chiu, Lien-Chung Wei","doi":"10.1111/hiv.70055","DOIUrl":"https://doi.org/10.1111/hiv.70055","url":null,"abstract":"","PeriodicalId":13176,"journal":{"name":"HIV Medicine","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144198906","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Free antiretrovirals as a key tool against the HIV pandemic: A systematic review.","authors":"Melissa Doutre, Marie-Pier Godin, Iliya Dmitriev, Ana Paula Pena-Gralle, Amy Bergeron, Lucie Blais, Benoît Lemire","doi":"10.1111/hiv.70051","DOIUrl":"https://doi.org/10.1111/hiv.70051","url":null,"abstract":"<p><strong>Background/objectives: </strong>Access to antiretroviral (ARV) drugs remains a critical challenge in achieving the WHO/UNAIDS 95-95-95 targets, with medication costs representing a substantial barrier. This systematic review evaluates the effect of free ARVs, without out-of-pocket cost to the patient, on the HIV cascade of care: the use of ARV therapy, viral suppression and the use of prophylaxis (PrEP).</p><p><strong>Methods: </strong>The following databases were searched for publications between 1 January 1996 and 10 July 2024: MEDLINE, Embase, CINAHL, CNKI, Global Index Medicus, the Web of Science, the SciELO Citation Index and grey literature. Publications were eligible if they included people living with or at risk of HIV and compared free access to ARVs with out-of-pocket fees. Reviewers screened publications that focused on the outcomes: being on therapy, being virally suppressed and being on PrEP. The National Heart, Lung and Blood Institute (NHLBI) and Joanna Briggs Institute (JBI) Quality Assessment Tools were used to assess publication quality.</p><p><strong>Results: </strong>A total of 34164 documents were identified, and 407 full-text manuscripts were reviewed. A total of 22 publications met the inclusion criteria. In six of the seven publications reporting on being on therapy, providing free ARVs increased the number of people who received treatment. All four publications reporting on viral suppression showed improvement with free access. Additionally, both publications reporting on PrEP use showed increased utilization with free access.</p><p><strong>Conclusions: </strong>The review offers valuable insights for countries considering implementing free ARV programmes. It suggests that expanding access to free ARVs helps achieve the global HIV targets and improve health outcomes.</p>","PeriodicalId":13176,"journal":{"name":"HIV Medicine","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144158130","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of treatment-emergent resistance-associated mutations and discontinuation due to adverse events among integrase strand transfer inhibitor-based single-tablet regimens and cabotegravir + rilpivirine for the treatment of virologically suppressed people with HIV: A systematic literature review and network meta-analysis.","authors":"Ishfaq Rashid, Nathan R Unger, Connor Willis, Teerapon Dhippayom, Moti Ramgopal, Elizabeth M Sherman, Nicholas Yared, Rachel Safran, Edwin Swiatlo, Amy R Weinberg, Soodi Navadeh, Howard Weston Schmutz, Nathorn Chaiyakunapruk","doi":"10.1111/hiv.70050","DOIUrl":"https://doi.org/10.1111/hiv.70050","url":null,"abstract":"<p><strong>Objective: </strong>This study evaluated rates of treatment-emergent resistance-associated mutations (TE-RAMs) and discontinuation due to adverse events (DC-AEs) across integrase strand transfer inhibitor (INSTI)-based single-tablet regimens and injectable cabotegravir + rilpivirine (CAB + RPV) in virologically suppressed people with HIV.</p><p><strong>Methods: </strong>A systematic literature review was conducted for phase 2-4 randomized controlled trials with ≥48 weeks of follow-up involving virologically suppressed people with HIV aged ≥12 years and published January 2003-March 2024. A random-effects network meta-analysis estimated comparative rates of TE-RAMs and DC-AEs among regimens at 48 weeks. Risk of bias and strength of evidence were assessed using Cochrane RoB and CINeMA, respectively.</p><p><strong>Results: </strong>Fourteen (7509 participants) and nine (4656 participants) studies were included in the TE-RAMs and DC-AEs analyses, respectively. No significant differences in rates of TE-RAMs were observed; risk ratios (RRs) for TE-RAMs for bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF), dolutegravir/abacavir/lamivudine (DTG/ABC/3TC) and CAB + RPV every 4 weeks (Q4W) versus CAB + RPV every 8 weeks (Q8W) were 0.22 (95% CI, 0.02-2.04), 0.22 (95% CI, 0.00-19.85) and 0.40 (95% CI, 0.14-1.09). Compared with CAB + RPV Q4W and Q8W, DC-AEs were significantly lower with B/F/TAF (RR, 0.15 [95% CI, 0.03-0.75] and RR, 0.16 [95% CI, 0.04-0.67], respectively) and DTG/ABC/3TC (RR, 0.05 [95% CI, 0.01-0.48] and RR, 0.05 [95% CI, 0.01-0.46], respectively).</p><p><strong>Conclusions: </strong>In virologically suppressed people with HIV, switching to CAB + RPV Q8W yielded a non-significant increased risk of TE-RAMs compared with INSTI-based 2- and 3-drug regimens and CAB + RPV Q4W. Both CAB + RPV Q4W and Q8W had significantly higher risks of DC-AEs than B/F/TAF and DTG/ABC/3TC. Findings highlight the importance of considering both resistance and tolerability when switching regimens.</p>","PeriodicalId":13176,"journal":{"name":"HIV Medicine","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144157897","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The silent crisis: Vertical HIV transmission and the struggle for antiretroviral access","authors":"Pérez-Cavazos Samantha,&nbsp;Pérez-Alba Eduardo,&nbsp;Camacho-Ortiz Adrián","doi":"10.1111/hiv.70052","DOIUrl":"10.1111/hiv.70052","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>Vertical transmission of HIV remains a critical and preventable aspect of the global HIV epidemic. Despite significant advancements in antiretroviral therapy (ART) and prevention strategies reducing mother-to-child transmission (MTCT) worldwide, a concerning disparity persists between what is medically achievable and the reality experienced in many communities.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This manuscript reviews the current landscape of MTCT of HIV, drawing on documented successes in elimination and identifying persistent barriers. It analyzes challenges related to therapeutic options for neonates, pharmaceutical supply chains, regulatory approval processes for neonatal ART, and the socio-ethical dimensions. Based on this analysis, a comprehensive five-point action plan is proposed to address these multifaceted issues.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The review highlights that 19 countries and territories have successfully eliminated MTCT of HIV, demonstrating the feasibility of this goal. However, significant barriers impede universal success. These include: 1) Limited availability of neonatal-specific ART formulations. 2) Pharmaceutical market dynamics driven by high-income countries. 3) Ethical and regulatory hurdles in conducting clinical trials for ART in neonates, hindering the generation of safety data. 4) MTCT is not just a medical problem but a profound social justice issue, exacerbated by stigma and discrimination.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Elimination of vertical HIV transmission is an attainable goal. The proposed action plan–encompassing strengthened antenatal screening, prompt ART initiation for pregnant women, guaranteed neonatal prophylaxis, robust supply chain management, and dedicated research and advocacy–offers a pathway to extend the possibility of an HIV-free start in life to every child, regardless of geographic or economic circumstance.</p>\u0000 </section>\u0000 </div>","PeriodicalId":13176,"journal":{"name":"HIV Medicine","volume":"26 7","pages":"1157-1159"},"PeriodicalIF":2.8,"publicationDate":"2025-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144150343","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"\"They didn't think we'd live this long\": A qualitative exploration of older adults living with HIV perspectives on geriatric care in Ontario.","authors":"Kristina M Kokorelias, Dean Valentine, Andrew D Eaton, Erica Dove, Esther Su, Christine L Sheppard, Stuart McKinlay, Paige Brown, Hardeep K Singh, Marina B Wasilewski, Ashley Flanagan, Alice Zhabokritsky, Reham Abdelhalim, Rabea Parpia, Rahel Zewude, Laura Jamieson, Sharon Walmsley, Luxey Sirisegaram","doi":"10.1111/hiv.70047","DOIUrl":"https://doi.org/10.1111/hiv.70047","url":null,"abstract":"<p><strong>Introduction: </strong>Advances in human immunodeficiency virus (HIV) care have increased life expectancy, leading to more older adults living with HIV. This study examines older adults' perspectives on geriatric healthcare needs.</p><p><strong>Methods: </strong>A community-based qualitative study in Ontario, Canada, recruited some adults aged 50+ years living with HIV through quota and purposive sampling. Quota sampling was used to include individuals of different ages, genders and ethno-racial backgrounds to capture a range of experiences. Data were collected via semi-structured interviews and focus groups, analyzed using the Qualitative Analysis Guide of Leuven.</p><p><strong>Results: </strong>Participants included interviewees (n = 14) and focus group attendees (n = 12). Four themes emerged: (1) lack of knowledge and access to geriatric care, highlighting service challenges; (2) healthcare providers' understanding of HIV and ageing, with stigma concerns; (3) role of social support networks for emotional/practical support; and (4) requirements for improved geriatric care, advocating provider education and greater social care access.</p><p><strong>Conclusions: </strong>Gaps in geriatric care for older adults with HIV highlight stigma, access issues and the need for education, virtual care and tailored, inclusive healthcare solutions.</p>","PeriodicalId":13176,"journal":{"name":"HIV Medicine","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144127425","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Metabolic syndrome and Pathobiological Determination of Atherosclerosis in Youth risk score in adolescents with and without perinatally acquired HIV in the Cape Town Adolescent and Antiretroviral Cohort (CTAAC)-Heart study.","authors":"Sahera Dirajlal-Fargo, Mothabisi Nyathi, Shan Sun, Lauren Balmert Bonner, Morné Kahts, Nana Akua Asafu-Agyei, Nomawethu Jele, Emma Carkeek, Justine Legbedze, Grace A McComsey, Matthew Feinstein, Landon Myer, Ntobeko A B Ntusi, Heather J Zar, Jennifer Jao","doi":"10.1111/hiv.70049","DOIUrl":"https://doi.org/10.1111/hiv.70049","url":null,"abstract":"<p><strong>Background: </strong>Limited data exist describing metabolic syndrome (MetS) and Pathobiological Determinants of Atherosclerosis in Youth (PDAY) coronary arteries (CA) and abdominal aorta (AA) risk scores in youth with HIV in sub-Saharan Africa.</p><p><strong>Methods: </strong>This cross-sectional analysis assessed MetS and PDAY CA and AA risk scores among youth with perinatally acquired HIV, youth with non-perinatally acquired HIV, and HIV-seronegative youth. Elevated PDAY score was defined as ≥1. Cluster heat map analysis was used, and logistic regression models were fit to assess the association of HIV status with MetS and PDAY CA and AA risk scores separately after adjusting for covariates.</p><p><strong>Results: </strong>We enrolled 237 youth with perinatally acquired HIV, 56 youth with non-perinatally acquired HIV and 71 HIV-seronegative youth; median (interquartile range = IQR) age was 18 (17, 20) years, 58% females. Youth with non-perinatally acquired HIV had the highest proportion with MetS (34%), while HIV-seronegative youth had 23%, and youth with perinatally acquired HIV 12%. Forty-seven percent of youth with perinatally acquired HIV, 63% of youth with non-perinatally acquired HIV and 41% of HIV-seronegative youth had elevated PDAY CA score; 30% of youth with perinatally acquired HIV, 39% of youth with non-perinatally acquired HIV and 23% of HIV-seronegative youth had elevated PDAY AA score. A non-overweight but hyperlipidaemic phenotype predominantly comprised of youth with perinatally acquired HIV was observed by cluster analysis. Youth with perinatally acquired HIV had lower adjusted odds of MetS compared with HIV-seronegative youth (odds ratio = 0.35, 95% confidence interval: 0.16, 0.79) but HIV status (either youth with perinatally acquired HIV or youth with non-perinatally acquired HIV vs. HIV-seronegative) was not associated with an elevated PDAY CA or AA risk score.</p><p><strong>Conclusion: </strong>Youth with perinatally acquired HIV have a lower odd of MetS, reflecting an overall non-overweight, but hyperlipidaemic phenotype highlighting the need for further cardiometabolic research in this ageing population in South Africa.</p>","PeriodicalId":13176,"journal":{"name":"HIV Medicine","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144119635","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"HIV seroconversions and genotypic viral resistance profiles in the PrEP impact trial.","authors":"Andrea Cartier, Ana Milinkovic, Lisa Goodall, Borja Mora-Peris, Dana Ogaz, Adrian Palfreeman, Branca Pereira, Iain Reeves, John Saunders, Ann K Sullivan","doi":"10.1111/hiv.70045","DOIUrl":"https://doi.org/10.1111/hiv.70045","url":null,"abstract":"<p><strong>Objectives: </strong>Here we describe HIV seroconversion events in participants of the PrEP Impact trial.</p><p><strong>Methods: </strong>Of 24 268 participants, we reviewed data for the 54 who were diagnosed with HIV during the trial; 11 at baseline.</p><p><strong>Results: </strong>Incidence was low for those diagnosed pre-pandemic at 0.13 per 100 person-years, and mainly linked to low self-reported adherence. The emergence of drug resistance in participants reporting recent oral PrEP (tenofovir disoproxil maleate with emtricitabine (TDF/FTC)) exposure was low (where analysis results are available, 21% of participants who seroconverted during trial participation showed drug resistance).</p><p><strong>Conclusions: </strong>Oral PrEP TDF/FTC is an effective HIV prevention intervention. Further data are needed to assess the prevalence and impact of increasing oral PrEP TDF/FTC use on HIV resistance.</p>","PeriodicalId":13176,"journal":{"name":"HIV Medicine","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144119634","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}